Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

Noble Capital initiated coverage of Gyre Therapeutics (GYRE) with an Outperform rating. Gyre is developing drugs for inflammatory diseases that ...

3.4 Pirfenidone as potential agents for the treatment of intestinal fibrosis Furthermore, studies have highlighted the role of the TRPA1 gene in fibrotic progression. Notably, both steroids (such as ...

A challenging treatment landscape Although drugs such as Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) are licensed in major markets, they can only slow ...

Currently approved treatments are Ofev and Roche's kinase inhibitor Esbriet (pirfenidone) – the latter now available in generic form – which have also been shown to slow down the decline in ...